Combination Therapy
Approved for: NSCLC
Non-small cell lung cancer. It is used: With carboplatin and either paclitaxel or paclitaxel albumin-stabilized nanoparticle formulation as first-line treatment for metastatic squamous disease.
The FDA has approved amivantamab-vmjw (Rybrevant) as the first treatment for adult patients with non–small cell lung cancer (NSCLC) who harbor EGFR exon 20 insertion mutations.